Lv11
42 积分 2025-09-25 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
6小时前
求助中
Use of Micro Botulinum Toxin for a Face-lifting Effect: A Systematic Review
7天前
已完结
Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis
7天前
已完结
Global prevalence of metabolic syndrome in patients with gout: A systematic review and meta-analysis
1个月前
已完结
Parent-reported prevalence of food allergy in Mexican schoolchildren: A population-based study
1个月前
已完结
Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye
2个月前
已完结
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
3个月前
已完结
Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours
3个月前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
5个月前
已完结
Precision Immunotherapy to Improve Sepsis Outcomes
6个月前
已完结
皖公网安备34019202002308
